Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive TCR Raises $5.8M to Invest in Clinical Applications

Premium

This story was originally published June 9.

Seattle-based Adaptive TCR, which provides immune repertoire sequencing services, has raised $5.8 million from private investors in a Series B investment round, the company reported last week.

The new financing adds to $4.5 million that the company secured last year, when it first launched its service (IS 7/20/2010).

This latest investment will be used to grow the company's immune system sequencing service, immunoSeq, and "invest in clinical applications in the oncology, autoimmune, and vaccine fields," CEO Chad Robins said in a statement.

According to Adaptive TCR, its platform can be used by biotech and pharmaceutical companies to predict whether patients will respond to certain therapeutics or vaccines. The company is currently testing its technology in a pilot program to sequence the T-cells and B-cells of volunteers, searching for marks of exposure to 17 different pathogens (CSN 4/12/2011).

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.